Months after acquiring Cambridge-based ReNAgade Therapeutics, Watertown’s Orna Therapeutics is laying off workers. Orna, a ...

Compared to DNA sequencing alone, concurrent DNA and RNA sequencing revealed more clinically actionable variants in NSCLC.

The firm has made significant strides in its RNA editing and RNA interference programs, which are attracting positive attention and positioning the company for differentiation in the treatment of ...

Orna was part of a buzzy cohort of companies established in the wake of the Covid pandemic, planning to create new, more ...

Nearly three decades later, drug makers have developed six approved small interfering RNA (siRNA) therapeutics in the ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

TD Cowen analyst Ritu Baral maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $78.00. The company’s shares closed yesterday at $46.73. Baral covers ...

Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...